Savara Inc. $SVRA Shares Bought by F m Investments LLC

F m Investments LLC grew its stake in shares of Savara Inc. (NASDAQ:SVRA) by 56.5% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 678,813 shares of the company’s stock after acquiring an additional 245,100 shares during the period. F m Investments LLC’s holdings in Savara were worth $4,093,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. VR Adviser LLC lifted its position in shares of Savara by 42.7% during the 3rd quarter. VR Adviser LLC now owns 12,681,043 shares of the company’s stock valued at $45,271,000 after acquiring an additional 3,796,780 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Savara by 20.8% during the 4th quarter. Vanguard Group Inc. now owns 10,041,647 shares of the company’s stock valued at $60,551,000 after acquiring an additional 1,728,453 shares during the last quarter. Nantahala Capital Management LLC lifted its position in shares of Savara by 5.4% during the 3rd quarter. Nantahala Capital Management LLC now owns 8,775,375 shares of the company’s stock valued at $31,328,000 after acquiring an additional 450,000 shares during the last quarter. Rosalind Advisors Inc. lifted its position in shares of Savara by 50.7% during the 3rd quarter. Rosalind Advisors Inc. now owns 4,000,000 shares of the company’s stock valued at $14,280,000 after acquiring an additional 1,345,056 shares during the last quarter. Finally, Swedbank AB lifted its position in shares of Savara by 54.5% during the 4th quarter. Swedbank AB now owns 850,000 shares of the company’s stock valued at $5,126,000 after acquiring an additional 300,000 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Price Performance

Shares of NASDAQ:SVRA opened at $5.23 on Friday. The company’s fifty day moving average is $5.43 and its two-hundred day moving average is $5.45. The company has a quick ratio of 11.85, a current ratio of 11.85 and a debt-to-equity ratio of 0.15. Savara Inc. has a 12-month low of $1.89 and a 12-month high of $7.01. The company has a market cap of $1.07 billion, a P/E ratio of -9.87 and a beta of 0.28.

Savara (NASDAQ:SVRA) last announced its earnings results on Friday, March 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). Equities analysts expect that Savara Inc. will post -0.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on SVRA. Wall Street Zen downgraded Savara from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. Oppenheimer began coverage on Savara in a research report on Friday, April 24th. They set an “outperform” rating and a $11.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a research note on Tuesday, April 21st. William Blair set a $10.00 target price on shares of Savara in a research note on Monday, March 16th. Finally, HC Wainwright reissued a “buy” rating on shares of Savara in a research note on Monday, March 16th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Savara has an average rating of “Moderate Buy” and an average price target of $9.13.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.